ICLR Stock Recent News

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK , July 29, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced its engagement with ICON Clinical Research Limited ("ICON") to expand it's Phase II Clinical Trial for cancer patients suffering from skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). Additional regulatory approval for the Phase II clinical trial is expected from potentially three EU countries in the upcoming months.

ICON Public Limited Company (NASDAQ:ICLR ) Q2 2025 Earnings Conference Call July 24, 2025 8:00 AM ET Company Participants Barry Balfe - Chief Operating Officer Kate Haven - Vice President of Investor Relations Nigel Clerkin - Chief Financial Officer Steven A. Cutler - CEO & Director Conference Call Participants Charles Rhyee - TD Cowen, Research Division David Howard Windley - Jefferies LLC, Research Division Elizabeth Hammell Anderson - Evercore ISI Institutional Equities, Research Division Eric White Coldwell - Robert W.

ICON may be relatively undervalued, trading at a ~10% discount to IQVIA and offering an attractive ~7% free cash flow yield that markets seem to be responding to now. The CRO sector faces near-term headwinds from a weak biotech funding environment related to high interest rates and associated increased clinical trial cancellations and delays. Q2 is indicating to markets that there will eventually be a return to growth after the CRO industry comes off the easy-money-fueled innovation environment.

Icon PLC (ICLR) came out with quarterly earnings of $3.26 per share, beating the Zacks Consensus Estimate of $3.18 per share. This compares to earnings of $3.75 per share a year ago.

DUBLIN--(BUSINESS WIRE)--ICON Announces Results of Annual General Meeting.

DUBLIN--(BUSINESS WIRE)--ICON Reports Second Quarter 2025 Results.

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR). ICON outpaced the average phase 1 performance scores of other large CROs, solidifying its position as a premier partner for early phase clinical.

According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (ICLR 0.92%) by selling 16,096 shares. The transaction was valued at $2.58 million.

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company's leadership position in the clinical research industry, cutting-edge innovation, its efforts in inclusion and sustainability, and as an employer of choice. Acknowledging ICON's leadership in the application of innovative AI technologies in the industry, the organisation.

LOS ANGELES--(BUSINESS WIRE)--ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm.